We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Silver Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Quantitative Test for Post-Transplant Pathogen Detection Improves Patient Outcomes

By LabMedica International staff writers
Posted on 12 May 2022
Print article
Image: Aptima CMV Quant Assay for human cytomegalovirus has received FDA approval (Photo courtesy of Hologic)
Image: Aptima CMV Quant Assay for human cytomegalovirus has received FDA approval (Photo courtesy of Hologic)

Cytomegalovirus (CMV) is a common virus that typically causes mild or asymptomatic infections in people with healthy immune systems. However, transplant recipients typically are artificially immunosuppressed to prevent transplant rejection, which makes them more vulnerable to infections. If left untreated, CMV infection can lead to severe disease, transplant rejection and even death. CMV monitoring as standard of care can help guide treatment decisions for transplant patients, depending on their risk and transplant organ type. Now, a new assay to quantify the viral load of CMV in patients who have had solid organ or stem cell transplants can support patient care following transplant surgery.

Aptima CMV Quant assay is the first test to be introduced in the U.S. by Hologic, Inc. (Marlborough, MA, USA) for post-transplant pathogen detection and monitoring. The assay is an in vitro nucleic acid amplification test for the quantification of human CMV DNA in human EDTA plasma and whole blood on the fully automated Panther system. The Aptima CMV Quant assay involves three main steps, which take place in a single tube on the Panther system: target capture, target amplification by TMA, and detection of the amplification products (amplicon) by the fluorescently labeled probes (torches). It is intended for use to aid in the diagnosis and to aid in the management of solid-organ transplant patients and hematopoietic stem cell transplant patients. The Aptima CMV Quant assay has received US FDA approval and is also CE-marked for diagnostic and viral load monitoring use in Europe.

“We have a legacy of innovation in viral load testing, and our Aptima CMV Quant assay is the first in a series of planned quantitative assays to support patient care following transplant surgery,” said Michelle Garsha, President, Diagnostic Solutions at Hologic. “We’re committed to providing our laboratory partners with superior solutions that improve workflow efficiency, support provider and patient needs and address the challenges faced by today’s molecular lab.”

“It is imperative to have highly accurate, reproducible results to monitor viral load trends of CMV infections over time in plasma of transplant patients,” added Karen Harrington, PhD, Head of Scientific Affairs for Diagnostic Solutions at Hologic. “Our assay aligns with the international quantitative standards, offering laboratories and healthcare providers confidence in the results each and every time, ultimately helping to enhance patient management and outcomes.”

Related Links:
Hologic, Inc. 

Gold Supplier
DP0150 Pulse 150
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.